Fellow Publications/Presentations
January through December 2016

Publications

1. Joshi M, Vasekar M, Grivas P, **Emamekhoo H**, Hsu J, Miller VA, Stephens PJ, Ali SM, Ross JS, Zhu J, Warrick J, Drabick JJ, Holder SL, Kaag M, Li M, Pal SK. Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. Oncotarget. 2016 May 18. doi: 10.18632/oncotarget.9449. [Epub ahead of print] PMID: 27213592

2. **Fu S**, Majhail NS. Supportive care in alternative donor transplantation. Semin Hematol. 2016 Apr;53(2):129-35. doi: 10.1053/j.seminhematol.2016.01.011. Review. PMID: 27000738

3. **Koshkin, VS,** Rini, BI. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016 June; 17(9): 1225-32. Doi: 10.1080/14656566.2016.1182987. PMID: 27112171

4. **Koshkin, VS**, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SN, Baker LH. Assessment of imaging modalities and response metrics in sarcoma – correlation with survival. Journal of Clin. Onc. 2016 Aug 29. pii: JCO681858. PMID: 27573658

5. **Madanat YF**, Smith MR, Almasan A, Hill BT. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood Lymphat Cancer. 2016;6:1-6. PMID: 27375364

6. **Menapace LA**, McCrae K, Khorana AA. Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. Thromb Res. 2016 Apr;140 Suppl 1:S93-8. PMID: 27067987

7. **Nazha A**, Narkhede M, Radivoyevitch T, Seastone DJ, Patel B, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA. Incorporation of Molecular Data into the Revised International Prognostic Scoring System in Treated Patients with Myelodysplastic Syndromes. Leukemia. 2016 Nov;30(11):2214-2220. Doi: 10.1038/leu.2016.138. PMID: 27311933

8. **Nazha A**, Prebet T, Gore S, Zeidan AM. Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?. Blood Rev. 2016 Apr 25. pii: S0268-960X(16)30014-5. doi: 10.1016/j.blre.2016.04.006. PMID: 27162201

9. **Nazha A**, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Al Ali N, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes at the Time of Hypomethylating Agent Failure. Haematologica. 2016 Mar 18. pii: haematol.2015.140962. PMID: 26992944

10. **Nazha A**, Gerds AT. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?. Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14. PMID: 26975864

11. **Nazha A**, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb;41:43-7. doi: 10.1016/j.leukres.2015.12.007. Epub 2015 Dec 22. PMID: 26777537

12. DiNardo CD, Garcia-Manero G, Pierce S, **Nazha A**, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016 Feb;91(2):227-32. doi: 10.1002/ajh.24252. PMID: 26799610

13. **Ornstein MC**, Wood L, Elson P, Allman K, Beach J, Martin A, Gilligan T, Garcia JA, Rini BI. Clinical Effect of Dose-Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer, 2016 Aug 18. pii:S1558-7673(16)30248-8. Doi: 10.1016/j.clgc.2016/08/014. [Epub ahead of print] PMID: 27625016

14. **Ornstein MC**, Rini BI. The Safety and Efficacy of Nivolumab for the Treatment of Advanced Renal Cell Carcinoma. Expert Rev Anticancer Ther. 2016; 16(6):577-8. PMID: 27144724

15. **Ornstein MC**, Rini BI. Pharmacokinetically-guided Dosing of Oral Drugs: True Precision Oncology? Clin Cancer Res. 2016;22(23):1-3. PMID: 27663599

16. **Ornstein MC**, Rini BI. Immunotherapy in Genitourinary Malignancies. Cancer Immunotherapy Principles and Practice. Demos Medical Publishing, New York. August 2016 (Book/Chapter).

17. **Ornstein MC**, Garcia JA, Sharifi N. Screening for Functional Kinases in Metastatic Prostate Cancer: a Glimmer of Hope for Kinase Inhibition. Transl Androl Urol. 2016;5(4):616-619.

18. **Ornstein MC**, Diaz CM, Rayman P, Elson P, Haywood S, Finke J, Garcia JA, Rini BI, Stephenson A, Campbell S, Fergany A, Emamekhoo H, Lamenza M, Miller S, Schach K, Profusek P, Tyler A, Ernstoff M, Hoimes C, Grivas P. Evaluation of Blood Tissue Myeloid Derived Suppressor Cells (MDSC), Clinicopathologic Factors, and Pathologic Response in Urothelial Carcinoma (UC). J Clin Oncol 34, 2016 (suppl; abstr e16010). 2016 ASCO Annual Meeting Proceedings. Online publication.

19. **Ornstein MC**, Wood LS, Elson P, Allman K, Beach J, Martin A, Zanick B, Grivas P, Gilligan T, Garcia JA, Rini BI. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma (mRCC). J Clin Oncol. Accepted for publication Nov 29, 2016.

20. **Ornstein MC**, Wood LS, Elson P, Allman K, Beach J, Martin A, Zanick B, Grivas P, Gilligan T, Garcia JA, Rini BI. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma (mRcc). J Clin Oncol. **PMID: Pending**

21. **Papadantonakis N**, Advani AS. Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol. 2016 Oct;7(5):252-269. Review. PMID: 27695616

22. **Sawalha Y**, Rouphail B, Jia X, Dean RM, Hill BT, Jagadeesh D, Pohlman BL, Smith MR. Is rituximab sub-optimally dosed in indolent B cell lymphoma? Br J Haematol. 2016 Sep;174(5):721-9. doi: 10.1111/bjh. 14114. Epub 2016 May 2. PMID: 27136331

23. **Thota S**, Sekeres MA. Combination therapies for MDS and AML: Does one plus one equal one? Leuk Lymphoma. 2016;57(3):505-6. Doi: 10.3109/10428194.2015.1102247. PMID: 26428702

24. **Tiwari S,** Mishra P, Abraham J. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor. Clin Breast Cancer. 2016 Oct; 16(5):344-348. Doi: 10.1016/j.clbc.2016.05.016. PMID: 27405796

25. **Tiwari SR**, Mishra P, Raska P, Calhoun B, Abraham J, Moore H, Budd GT, Fanning A, Valente S, Steward R, Grobmyer SR, Montero AJ. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2016 Jul; 185(1): 189-93. Doi: 10.1007/s10549-016-3866-0. PMID: 27324504

26. **Varella L**, Moore HC. Aromatase inhibitors as adjuvant therapy for breast cancer: is longer treatment better? J Clin Outcomes Manag. November 2016, Vol 23, No. 11.

27. Dutcher JP, Wiernik PH, **Varella L**, Chintapatla R. Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families. Fam Cancer. 2016 Oct; 15(4):677-87. PMID: 27334456

28. **Zahoor H**, Rini BI. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. Expert Opin Emerg Drugs. 2016 Oct 3. [Epub ahead of print]. PMID: 27690664

Poster Presentations/Abstracts

1. Grivas P, **Emamekhoo H**, McKenney, et. al. Evaluation of Immune Checkpoints PD1, PDL1, PDL2, as Predictors of Response to Chemotherapy (CTX) and Outcome in Bladder Cancer (BC). Immuno-Oncology Young Investigaros Forum, Houston, TX. March 2016 (Oral)

2. **Koshkin V**, Grivas P, Rini BI, Garcia J, Chen Y. Phase II Trial of Neoadjuvant Lirilumab/Nivolumab in Cisplatin-ineligible Muscle-Invasive Bladder Cancer. AACR/ASCO Vail Workshop. July 2016

3. **Koshkin, V**, Grivas P. Phase II Feasibility Trial of Neoadjuvant Lirilumab/Nivolumab in Cisplatin-ineligble Muscle-Invastive Bladder Cancer. EGOC-ACRIN Fall Meeting Presentation. November 2016.

4. **Kruse M**, Raska P, Budd GT, Montero A, Grobmyer S, Abraham J, Moore H. Impact of institution of young women's breast cancer clinic on time to treatment (TTT) and utilization of fertility, genetics and social work consultations in women under age 50 with new diagnosis of early stage breast cancer (ESBC). 2016 San Antonio Breast Cancer Symposium, San Antonio, TX. Dec 2016. (Poster)

5. **Kruse M**. Phase II study evaluating efficacy of mirvetuximab soravtansine monotherapy in folate receptor-α expressing metastatic triple-negative breast cancer. AACR/ASCO Vail Workshop. July 2016

6. **Ornstein MC**, Stephenson AS, Elson P, Tyler AJ, Profusek P, Grivas P, Rini BI, Klein EA, Garcia JA. Adjuvant Enzalutamide (Enza) for Men with High-Risk Prostate Cancer (HRPCa) after Radical Prostatectomy (RP). J Clin Onc 34, 2016 (Suppl; abstr 5071). 2016 ASCO Annual Meeting. (Poster)

7. **Ornstein MC**, Diaz CM, Rayman P, Elson P, Haywood S, Finke J, Garcia JA, Rini BI, Stephenson A, Campbell S, Fergany A, Emamekhoo H, Lamenza M, Stybor S, Schach K, Profusek P, Tyler A, Ernstoff M, Grivas P. Correlation of Myeloid Derived Suppressor Cell (MDSC) Populations with Clinicopathologic Features in Urothelial Carcinoma (UC). J Clin Oncol 34, 2016 (suppl 2s; abstr 434). 2016 ASCO GU Meeting. (Poster)

8. **Patel B**, Saygin C, Przychodzen B, et. al. Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes. ASH Annual Meeting. December 2016 (Poster)

9. **Patel B**, Przychodzen B, Clemente M, Hirsch C, et. al. Clonal Dynamics of Refractory Aplastic Anemia in Patients Treated with Eltrombopag. ASH Annual Meeting. December 2016 (Poster)

10. **Patel B**, Saygin C, Przychodzen B, Hirsch C, et. al. Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. ASH Annual Meeting. December 2016 (Poster)

11. **Patel S**, Rybicki L, Abounader D, Bolwell B, et. al. Prognostic Factors for Late Mortality among Day 100 Survivors after Allogenic Hematopoietic Cell Transplantation (HCT). ASH Annual Meeting. December 2016 (Poster)

12. **Patel S**, Radivoyevitch T, Gerds A, Majhail N, et. al. Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy. ASH Annual Meeting. December 2016 (Poster)

13. **Patel S**, Rybicki L, Abounader D, Dumont C, et. al. Prognostic Effect of Bone Marrow (BM) and Peripheral Blood Stem Cell (PBSC) Donor Cell Subsets on Myeloblative Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes. ASH Annual Meeting. December 2016 (**Oral**)

14. **Patel, S**. A Prospective Trial Investigating the Use of Patient-Reported Outcome Assessments in Acute Graft Versus Host Disease. AACR/ASCO Vail Workshop. July 2016

15. **Patel S**, Radivoyevitch T, Gerds A, Majhail N, et. al. Thirty-year analysis of randomized clinical trials in patients with acute myeloid leukemia. ASCO Annual Meeting. Merit Award. June 2016 (Poster)

16. **Thota S**, Sanikommu S, Patel BJ, Sadaps M, et. al. Subcutaneious low dose alemtuzumab: role as a salvage therapy in immune – mediated marrow failure conditions. ASH Annual Meeting. December 2016 (Poster)

17. **Tiwari S**, Raska P, Moore H, Emamekhoo E, et. al. Improved outcomes in stage I HER2 postivie breast cancer patients treated with trastuzumab and chemotherapy. ASCO Annual Meeting. June 2016 (Poster)

18. Hong S, **Varella L**, Tullio K, Moore HC, Budd GT, Grobmyer SR, Montero AJ, Schnur G, Abraham J. Use of imaging studies for early-stage breast cancer at Cleveland Clinic. ASCO Annual Meeting. June 2016. J Clin Oncol 34, 2016 (Suppl; abstr e18217). (Poster)

19. **Winter A**, Landsburg D, Hernandez-Iizaliturri F, et. al. A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib. ASH Annual Meeting. December 2016 (**Oral**)